Viking Therapeutics, Inc. (VKTX) |
|
4.01 -0.08 (-1.96%)
|
11-25 13:00 |
|
Open: |
4.06 |
Pre. Close: |
4.09 |
|
High:
|
4.075 |
Low:
|
3.98 |
|
Volume:
|
161,722 |
Market Cap:
|
308(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 2:01:18 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.97  One year: 5.43 |
| Support: |
Support1: 3.63 Support2: 3.02 |
| Resistance: |
Resistance1: 4.26 Resistance2: 4.65 |
| Pivot: |
4.16  |
| Moving Average: |
MA(5): 4.03 MA(20): 4.19
MA(100): 3.49 MA(250): 3.36 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 24.9 %D(3): 22.6 |
| RSI: |
RSI(14): 50.3 |
| 52-week: |
High: 5.32 Low: 2.01 |
| Average Vol(K): |
3-Month: 773 (K) 10-Days: 740 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VKTX ] has closed above bottom band by 19.5%. Bollinger Bands are 44.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.18 - 4.2 |
4.2 - 4.22 |
|
Low:
|
4.02 - 4.04 |
4.04 - 4.05 |
|
Close:
|
4.06 - 4.09 |
4.09 - 4.12 |
|
Company Description |
|
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. |
Headline News |
Mon, 21 Nov 2022
15 Most Volatile Stocks to Buy Now - Yahoo Finance
Wed, 02 Nov 2022
How Will the Market React to Viking Therapeutics Inc (VKTX) Stock Getting a Bullish Rating - InvestorsObserver
Fri, 28 Oct 2022
Viking Therapeutics (NASDAQ:VKTX) has raised its price target to $11.00. - Best Stocks
Thu, 27 Oct 2022
BMRN Faces FDA In March, ALGN's Q3 Results Disappoint, VKTX Awaits VOYAGE… - Nasdaq
Tue, 18 Oct 2022
Is Viking Therapeutics Inc (VKTX) Stock a Smart Value Tuesday? - InvestorsObserver
Thu, 13 Oct 2022
Where Will Viking Therapeutics Inc (VKTX) Stock Go Next After It Has Risen 6.44% in a Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
77 (M) |
| Shares Float |
68 (M) |
|
% Held by Insiders
|
11.6 (%) |
|
% Held by Institutions
|
35.7 (%) |
|
Shares Short
|
1,900 (K) |
|
Shares Short P.Month
|
1,880 (K) |
Stock Financials |
|
EPS
|
-0.74 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.83 |
|
EPS Est Next Year
|
-0.81 |
|
Book Value (p.s.)
|
1.97 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-20 |
|
Return on Equity (ttm)
|
-33.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-50 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-5.48 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
2.03 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-6.18 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
